In recent years, researchers and medication designers have focused more on new nanotechnology approaches to improve drug delivery to the central nervous system (CNS). Nanotechnology holds great promise for improving neurological disorders treatment, primarily Alzheimer's disease, Parkinson's disease, brain tumours, and stroke.[1]In order to treat retinal illnesses, nanotechnology-based medications can offer a crucial platform for sustaining, releasing, and a targeted targeting design. The most popular biocompatible and biodegradable polymer that has been authorised by the Food and Drug Administration is poly-lactic-co-glycolic acid. The development of specialised instruments for the slow and reliable delivery of proteins, other macromolecules, and small-molecule medications has been the subject of numerous investigations.[2]Because of their small size(10–100 nm), which enhances circulation and permits superior accumulation of therapeutic medications at the tumour sites, nanotechnology is used in drug delivery. Passive targeting will be made possible by the use of nanotechnology in the future, and targeting moieties will allow for even more advancements.[3]In the pharmaceutical biotechnology industry, nanoparticles enhance the therapeutic index and offer answers for potential delivery issues with novel kinds of "biotech" medications, such as oligonucleotides and recombinant proteins. The subject of this review is nanoparticulate drug carriers.technologies, other than liposomes, that are currently in use, as well as the potential and constraints of nanoparticles in the field ofbiotechnology in pharmaceuticals